Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 2/20 | 0.45 |
| ▸ | GNRHR | P30968 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22372184 | 0.80 | HIF1A (0.45) | KDM4EGLSNAMPT | |
| SCHEMBL16762587 | 0.80 | KDM4E (0.59) | KDM4EPKMFPR3FPR2GNRHR | |
| SCHEMBL6984094 | 0.79 | KDM4E (0.71) | KDM4EPKMTP53RORCNAMPT | |
| SCHEMBL15795679 | 0.78 | GPR119 (0.48) | KDM4EPKMGLS | |
| SCHEMBL17594570 | 0.78 | KDM4E (0.59) | KDM4EPKMGNRHRTP53 | |
| SCHEMBL16825871 | 0.77 | KDM4E (0.79) | KDM4EPKMFPR3FPR2GNRHR | |
| SCHEMBL26131403 | 0.77 | KDM4E (1.00) | KDM4EPKMTP53NAMPTKMT2A | |
| SCHEMBL25195749 | 0.77 | KDM4E (0.61) | KDM4EPKMFPR3FPR2GNRHR | |
| SCHEMBL8206262 | 0.77 | KDM4E (0.64) | KDM4EPKMGNRHRTP53RORC | |
| SCHEMBL13947430 | 0.76 | KDM4E (0.80) | KDM4EPKMGNRHRTP53RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708294-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708294-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708294-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2723173-B1 | TRIAZOLE DERIVATIVES USEFUL AS NICOTINIC RECEPTOR ANTAGONISTS | INTRA CELLULAR THERAPIES INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9469625-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469625-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469625-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160237061-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237061-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237061-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20140205596-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205596-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205596-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2723173-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012178112-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012178112-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205596-A1 | ORGANIC COMPOUNDS | CHRNG, CHRM3, CHRNB1 | KDM4E 3525/4885PKM 3224/4885FPR3 1406/4885 |
| US-20160237061-A1 | ORGANIC COMPOUNDS | CHRNG, CHRM3, CHRNB1 | KDM4E 3525/4885PKM 3224/4885FPR3 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.